Odyssey completes journey to NASDAQ: Public Equity Report

As immunology-focused Odyssey finally found its way to NASDAQ this week, a handful of biotechs with clinical catalysts also priced follow-ons, with three raising a total of more than $1.5 billion.

Odyssey Therapeutics Inc. (NASDAQ:ODTX) spent most of 2025’s first half in the IPO queue before withdrawing its bid in June. This spring, however, the immunology company found the markets more receptive; it filed again in April, and priced its IPO late Thursday...